S'abonner

The global burden of tuberculosis: results from the Global Burden of Disease Study 2015 - 23/02/18

Doi : 10.1016/S1473-3099(17)30703-X 

GBD Tuberculosis Collaborators

Hmwe H Kyu, Emilie R Maddison, Nathaniel J Henry, John Everett Mumford, Ryan Barber, Chloe Shields, Jonathan C Brown, Grant Nguyen, Austin Carter, Timothy M Wolock, Haidong Wang, Patrick Y Liu, Marissa Reitsma, Jennifer M Ross, Amanuel Alemu Abajobir, Kalkidan Hassen Abate, Kaja Abbas, Mubarek Abera, Semaw Ferede Abera, Habtamu Abera Hareri, Muktar Ahmed, Kefyalew Addis Alene, Nelson Alvis-Guzman, Joshua Amo-Adjei, Jason Andrews, Hossein Ansari, Carl Abelardo Antonio, Palwasha Anwari, Hamid Asayesh, Tesfay Mehari Atey, Sachin Atre, Aleksandra Barac, Justin Beardsley, Neeraj Bedi, Isabela Bensenor, Addisu Shunu Beyene, Zahid Ahmad Butt, Pere-Joan Cardona, Devasahayam Christopher, Lalit Dandona, Rakhi Dandona, Kebede Deribe, Amare Deribew, Rebecca Ehrenkranz, Maysaa El Sayed Zaki, Aman Endries, Tesfaye R Feyissa, Florian Fischer, Ruoyan Gai, Alberto L Garcia-Basteiro, Tsegaye Tewelde Gebrehiwot, Hailay Gesesew, Belete Getahun, Philimon Gona, Amador Goodridge, Harish Gugnani, Hassan Haghparast-Bidgoli, Gessessew Bugssa Hailu, Hamid Yimam Hassen, Esayas Hilawe, Nobuyuki Horita, Kathryn H Jacobsen, Jost B Jonas, Amir Kasaeian, Muktar Sano Kedir, Laura Kemmer, Yousef Khader, Ejaz Khan, Young-Ho Khang, Abdullah T Khoja, Yun Jin Kim, Parvaiz Koul, Ai Koyanagi, Kristopher J Krohn, G Anil Kumar, Michael Kutz, Rakesh Lodha, Hassan Magdy And El Razek, Reza Majdzadeh, Tsegahun Manyazewal, Ziad Memish, Walter Mendoza, Haftay Berhane Mezgebe, Shafiu Mohammed, Felix Akpojene Ogbo, In-Hwan Oh, Eyal Oren, Aaron Osgood-Zimmerman, David Pereira, Dietrich Plass, Farshad Pourmalek, Mostafa Qorbani, Anwar Rafay, Mahfuzar Rahman, Rajesh Kumar Rai, Puja C Rao, Sarah E Ray, Robert Reiner, Nickolas Reinig, Saeid Safiri, Joshua A Salomon, Logan Sandar, Benn Sartorius, Morteza Shamsizadeh, Muki Shey, Desalegn Markos Shifti, Hirbo Shore, Jasvinder Singh, Chandrashekhar T Sreeramareddy, Soumya Swaminathan, Scott J Swartz, Fentaw Tadese, Bemnet Amare Tedla, Balewgizie Sileshi Tegegne, Belay Tessema, Roman Topor-Madry, Kingsley Nnanna Ukwaja, Olalekan A. Uthman, Vasiliy Vlassov, Stein Emil Vollset, Tolassa Wakayo, Solomon Weldegebreal, Ronny Westerman, Abdulhalik Workicho, Naohiro Yonemoto, Seok-Jun Yoon, Marcel Yotebieng, Mohsen Naghavi, Simon I Hay, Theo Vos, Christopher JL Murray


Summary

Background

An understanding of the trends in tuberculosis incidence, prevalence, and mortality is crucial to tracking of the success of tuberculosis control programmes and identification of remaining challenges. We assessed trends in the fatal and non-fatal burden of tuberculosis over the past 25 years for 195 countries and territories.

Methods

We analysed 10 691 site-years of vital registration data, 768 site-years of verbal autopsy data, and 361 site-years of mortality surveillance data using the Cause of Death Ensemble model to estimate tuberculosis mortality rates. We analysed all available age-specific and sex-specific data sources, including annual case notifications, prevalence surveys, and estimated cause-specific mortality, to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how observed tuberculosis incidence, prevalence, and mortality differed from expected trends as predicted by the Socio-demographic Index (SDI), a composite indicator based on income per capita, average years of schooling, and total fertility rate. We also estimated tuberculosis mortality and disability-adjusted life-years attributable to the independent effects of risk factors including smoking, alcohol use, and diabetes.

Findings

Globally, in 2015, the number of tuberculosis incident cases (including new and relapse cases) was 10·2 million (95% uncertainty interval 9·2 million to 11·5 million), the number of prevalent cases was 10·1 million (9·2 million to 11·1 million), and the number of deaths was 1·3 million (1·1 million to 1·6 million). Among individuals who were HIV negative, the number of incident cases was 8·8 million (8·0 million to 9·9 million), the number of prevalent cases was 8·9 million (8·1 million to 9·7 million), and the number of deaths was 1·1 million (0·9 million to 1·4 million). Annualised rates of change from 2005 to 2015 showed a faster decline in mortality (−4·1% [−5·0 to −3·4]) than in incidence (−1·6% [−1·9 to −1·2]) and prevalence (−0·7% [−1·0 to −0·5]) among HIV-negative individuals. The SDI was inversely associated with HIV-negative mortality rates but did not show a clear gradient for incidence and prevalence. Most of Asia, eastern Europe, and sub-Saharan Africa had higher rates of HIV-negative tuberculosis burden than expected given their SDI. Alcohol use accounted for 11·4% (9·3–13·0) of global tuberculosis deaths among HIV-negative individuals in 2015, diabetes accounted for 10·6% (6·8–14·8), and smoking accounted for 7·8% (3·8–12·0).

Interpretation

Despite a concerted global effort to reduce the burden of tuberculosis, it still causes a large disease burden globally. Strengthening of health systems for early detection of tuberculosis and improvement of the quality of tuberculosis care, including prompt and accurate diagnosis, early initiation of treatment, and regular follow-up, are priorities. Countries with higher than expected tuberculosis rates for their level of sociodemographic development should investigate the reasons for lagging behind and take remedial action. Efforts to prevent smoking, alcohol use, and diabetes could also substantially reduce the burden of tuberculosis.

Funding

Bill & Melinda Gates Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 3

P. 261-284 - mars 2018 Retour au numéro
Article précédent Article précédent
  • Looking at India’s sanitation divide
  • Bipin Adhikari, Shiva Raj Mishra
| Article suivant Article suivant
  • Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
  • Antoni Torres, Nanshan Zhong, Jan Pachl, Jean-François Timsit, Marin Kollef, Zhangjing Chen, Jie Song, Dianna Taylor, Peter J Laud, Gregory G Stone, Joseph W Chow

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.